Loading...
ALVR109, an off-the-shelf partially HLA matched SARS-CoV-2-specific T cell therapy, to treat refractory severe COVID-19 pneumonia in a heart transplant patient: Case report
Martits-Chalangari, Katalin Spak, Cedric W. Askar, Medhat Killian, Aaron Fisher, Tammy L. Atillasoy, Ercem Marshall, William L. McNeel, David Miller, Michael D. Mathai, Susan K.
Martits-Chalangari, Katalin
Spak, Cedric W.
Askar, Medhat
Killian, Aaron
Fisher, Tammy L.
Atillasoy, Ercem
Marshall, William L.
McNeel, David
Miller, Michael D.
Mathai, Susan K.
Citations
Altmetric:
Soloist
Composer
Publisher
Wiley
Date
2021
Additional date(s)
Abstract
An unvaccinated adult male heart transplant recipient patient with recalcitrant COVID-19 due to SARS-CoV-2 delta variant with rising nasopharyngeal quantitative viral load was successfully treated with ALVR109, an off-the-shelf SARS-CoV-2-specific T cell therapy. Background immunosuppression included 0.1 mg/kg prednisone, tacrolimus, and mycophenolate mofetil 1 gm twice daily for historical antibody-mediated rejection. Prior therapies included remdesivir, corticosteroids, and tocilizumab, with requirement for high-flow nasal oxygen. Lack of clinical improvement and acutely rising nasopharyngeal viral RNA more than 3 weeks into illness prompted the request of ALVR109 through an emergency IND. The day following the first ALVR109 infusion, the patient's nasopharyngeal SARS-CoV-2 RNA declined from 7.43 to 5.02 log(10) RNA copies/ml. On post-infusion day 4, the patient transitioned to low-flow oxygen. Two subsequent infusions of ALVR109 were administered 10 and 26 days after the first; nasopharyngeal SARS-CoV-2 RNA became undetectable on Day 11, and he was discharged the following day on low-flow oxygen 5 weeks after the initial diagnosis of COVID-19. The clinical and virologic improvements observed in this patient following administration of ALVR109 suggest a potential benefit that warrants further exploration in clinical trials.
Contents
Subject
antibiotic: antiviral
clinical research/practice
heart transplantation/cardiology
immunobiology
infection and infectious agents-viral: SARS-CoV-2/COVID-19
infectious disease
clinical research/practice
heart transplantation/cardiology
immunobiology
infection and infectious agents-viral: SARS-CoV-2/COVID-19
infectious disease
Subject(s)
Research Projects
Organizational Units
Journal Issue
Genre
Description
Format
Department
Burnett School of Medicine